# SLE Digital Twin Living Requirements Specification (SLE-DT LRS)

## Revision Status
Integrated Literature Reviews
1. SLE DEG Bioinformatics Review.
2. AI, Biomarkers, and Precision Rheumatology Review.
3. Digital Twins and the Metaverse in Healthcare Review.
4. AI Autoimmune Research Trends (2025 Bibliometric Analysis).
5. AI for Systemic Lupus Erythematosus Personalized Treatment.

---

## Canonical Thesis Direction
### Selected MVP Architecture
Transcriptomics-First + Molecular-Endotype-Aware Healthcare Digital Twin.

### Scope Decision
MVP focus: Systemic Lupus Erythematosus (SLE), transcriptomics, immune-state modeling, molecular endotypes, and immune-tolerance restoration.

### Research Objective Representation
The Digital Twin represents:
- Patient immune state.
- Disease-state deviation from health.
- Molecular endotypes.
- Active biological pathways.
- Candidate immune restoration opportunities.

---

## Executive Thesis Objective
Develop an explainable Digital Twin that models patient-specific immune dysregulation, discovers molecular endotypes, identifies disease-driving pathways, simulates immune-tolerance restoration, and generates biologically plausible therapeutic hypotheses.

---

## MVP Requirements
### Included
- Public GEO transcriptomic datasets.
- Healthy control cohorts.
- Healthy reference twin.
- Patient-specific twin.
- DEG analysis.
- Pathway analysis.
- PPI analysis.
- Molecular endotype identification.
- Explainable target ranking.
- Virtual perturbation simulation.
- Technical validation.
- Biological validation.

### Out of Scope
- Clinical deployment.
- Drug recommendation.
- Wet-lab validation.
- Multi-omics integration.
- Wearables.
- EHR integration.
- Real-time monitoring.

---

## Scientific Foundation
### Core Biological Themes
1. Immune tolerance restoration.
2. Molecular heterogeneity.
3. Patient stratification.
4. Explainable AI.

### Neutrophil Biology
Mandatory pathway class.

### Interferon Biology
Mandatory pathway class.

### B-Cell Biology (NEW)
B-cell activity and autoantibody-driven disease mechanisms shall be treated as first-class biological concepts in the SLE-DT framework.

### T-Cell Regulatory Biology (NEW)
Future architecture should support characterization of distinct T-cell functional states and their relationship to disease progression.

### Priority Hub Genes
- CCNB2
- CDCA8
- AURKB
- BUB1B
- RRM2
- BIRC5
- UBE2C

---

## Molecular Endotype Requirements
Disease subtyping is a foundational requirement of the Digital Twin.

### Required Signals
- Gene-expression signatures.
- Pathway activity profiles.
- Interferon activity.
- Immune-state signatures.
- B-cell related signatures.

### Outputs
- Endotype definitions.
- Patient clusters.
- Endotype-specific disease drivers.
- Endotype-specific restoration opportunities.

---

## Biomarker Framework
### MVP Biomarkers
- DEGs.
- Pathway signatures.
- Hub genes.
- Endotype signatures.

### Future Biomarkers
- Genomics.
- Proteomics.
- Epigenomics.
- Cytokine profiling.
- Immune-cell phenotyping.
- Imaging biomarkers.
- Digital biomarkers.

### Design Principle
Composite biomarker strategies are the preferred long-term direction.

---

## Digital Twin Architecture Requirements
1. Data ingestion.
2. QC and normalization.
3. DEG engine.
4. Pathway engine.
5. Network engine.
6. Endotype engine.
7. Healthy twin.
8. Patient twin.
9. Twin comparison.
10. Perturbation engine.
11. Explainability engine.
12. Target ranking engine.
13. Validation engine.

---

## Future AI Capability Roadmap
### Single-Cell Extensions
- scRNA-seq integration.
- Automated cell-state annotation.
- Cell-state discovery.
- Cell-population Digital Twins.

### Immune Cell Modeling
- B-cell state modeling.
- T-cell state modeling.
- Immune-cell interaction discovery.

### Multi-Omics Digital Twin
- Transcriptomics.
- Genomics.
- Epigenomics.
- Proteomics.
- Immune phenotyping.
- Clinical data integration.

### Precision Therapeutics
- Treatment-response prediction.
- Endotype-guided intervention discovery.
- Personalized therapeutic hypothesis generation.

---

## Data Strategy
Healthy-control cohorts are a first-class requirement.

Dataset documentation should include:
- Age.
- Sex.
- Ethnicity.
- Disease subtype.
- Clinical metadata.
- Cohort provenance.

---

## Validation Framework
### Technical
- Reproducibility.
- Stability.
- Sensitivity analysis.
- Cross-dataset consistency.

### Biological
Recover:
- Neutrophil pathways.
- Interferon pathways.
- B-cell relevant signatures.
- Published hub genes.

---

## Open Research Questions
1. Can deep learning outperform DEG-to-PPI workflows?
2. Which hub genes remain important under graph-learning approaches?
3. Can ML recover biologically meaningful genes removed by traditional thresholds?
4. How accurately can transcriptomics alone predict therapeutic targets?
5. Are public longitudinal SLE cohorts available?
6. How should production Digital Twins implement drift monitoring?
7. Can subtype-specific twins outperform generalized twins?
8. How should wearable-derived biomarkers be integrated?
9. Which public datasets contain both molecular and digital-health data?
10. What minimum biomarker set is necessary for a clinically useful lupus twin?
11. Has a fully customizable patient-specific SLE Digital Twin already been demonstrated?
12. Which healthcare DT category best aligns with lupus research goals?
13. Would an organ-specific lupus DT provide sufficient MVP value?
14. Should architecture evolve toward system-wide or organ-specific twins?
15. Which lupus target organ provides highest-value future organ-level twin?
16. Are existing lupus organ simulation platforms available?
17. Which biological, clinical, behavioral, and environmental variables are essential?
18. Are datasets from B-cell-targeting therapy studies publicly available?
19. Which SLE subtype is the most achievable MVP target?
20. Which sequencing and genome-analysis tools are most established in SLE research?
21. Can multi-omics AI models reliably predict individual treatment response?

### Questions Resolved From Literature
- Disease subtyping is a foundational requirement.
- SLE molecular heterogeneity is a primary design driver.
- Transcriptomics is an appropriate MVP modality.
- Patient-specific Digital Twins are a meaningful research direction.
- Multi-omics should remain a future-phase capability.

---

## Expected Thesis Contributions
- Explainable SLE Digital Twin architecture.
- Molecular-endotype-aware disease modeling.
- Immune-tolerance restoration framework.
- Neutrophil, interferon, and B-cell-aware prioritization.
- Validation-oriented healthcare DT methodology.
- Reproducible research platform.

---

## References (IEEE)
[1] Zhao et al., Identification of Biomarkers and Pathways in SLE.
[2] GEO GSE162828.
[3] GEO GSE169080.
[4] STRING.
[5] Cytoscape.
[6] limma.
[7] AI, Biomarkers, and Precision Medicine in AIRDs.
[8] Digital Twins and the Metaverse in Healthcare and Industry.
[9] AI and Autoimmune Disease Research Trends (2025).
[10] AI for Systemic Lupus Erythematosus Personalized Treatment.
